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Kallikrein-6 and calpain-1 are amongst a small group of proteases that degrade α-synuclein. We have explored the
possibility that reduction in the level or activity of these enzymes contributes to the accumulation of α-synuclein in
Lewy body diseases. We measured calpain-1 activity by fluorogenic activity assay, kallikrein-6 level by sandwich
ELISA, and levels of α-synuclein and α-synuclein phosphorylated at serine 129 (α-synuclein-P129), in post-mortem
brain tissue in pure dementia with Lewy bodies (DLB, n = 12), Alzheimer’s disease (AD, n = 20) and age-matched
controls (n = 19). Calpain-1 activity was significantly reduced in DLB within the cingulate and parahippocampal
cortex, regions with highest α-synuclein and α-synuclein-P129 load, and correlated inversely with the levels of
α-synuclein and α-synuclein-P129. Calpain-1 was unaltered in the thalamus and frontal cortex, regions with less
α-synuclein pathology. Kallikrein-6 level was reduced in the cingulate cortex in the DLB cohort, and correlated inversely
with α-synuclein and α-synuclein-P129. Kallikrein-6 was also reduced in DLB in the thalamus but not in relation
to α-synuclein or α-synuclein-P129 load and was unaltered in the frontal and parahippocampal cortex. In SH-SY5Y
cells overexpressing wild-type α-synuclein there was partial co-localisation of kallikrein-6 and calpain-1 with α-synuclein,
and siRNA-mediated knock-down of kallikrein-6 and calpain-1 increased the amount of α-synuclein in cell lysates. Our
results indicate that reductions in kallikrein-6 and calpain-1 may contribute to the accumulation of α-synuclein in DLB.
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Abnormal aggregation of α-synuclein (α-syn) within neur-
onal perikarya (Lewy bodies) and neurites (Lewy neurites)
are defining neuropathological hallmarks of Parkinson’s
disease (PD) and dementia with Lewy bodies (DLB). There
is accumulation of both insoluble [1] and soluble oligo-
meric α-syn [2] in sporadic PD and DLB without an in-
crease in α-syn mRNA [3,4], suggesting a major role for
impaired clearance in the pathogenesis of PD and DLB.
Several genetic mutations that cause PD (e.g. in PINK1,
PARK2, LRRK2) involve proteins associated with the
ubiquitin-proteasome system (UPS) and the autophagy-
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unless otherwise stated.α-syn clearance (reviewed in [5-8]) and are dysregulated
in sporadic PD and DLB. Cathepsin D (CTSD) the major
lysosomal protease responsible for α-syn cleavage [9-11] is
upregulated in PD and DLB [12]. A small number of non-
lysosomal proteolytic enzymes have been identified that
cleave α-syn in vitro, including MPP-3, −9 [13], calpain-1
(CAPN1) [14,15] and kallikrein-6 (KLK6) [16,17]. These
are expressed within the cytosol, plasma membrane or are
secreted extracellularly.
KLK6 (also known as neurosin) is a serine protease pre-
dominantly expressed within the brain, especially in neu-
rons and oligodendrocytes [18-20]. In vitro, KLK6 degrades
monomeric α-syn within the NAC region, essential for fila-
ment assembly, and protects against α-syn aggregation and
neurotoxicity [16,17]. KLK6 co-localises with α-syn in Lewy
bodies in post-mortem brain tissue in PD [16,21]. Direct
interaction between KLK6 and α-syn in mouse brain wasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Cases studieda
Age-at-death (y) Gender (M:F) Post-mortem
delay (h)
Control (n = 19) 80.3 ± 9.0b 14:5 37.4 ± 14.3b
DLB (n = 12) 76.8 ± 9.1 7:5 27.7 ± 9.1
AD (n = 20) 79.4 ± 7.3 8:12 28.2 ± 16.3
aFor a full list of all cases with MRC brain bank identifiers please see Additional
file 1: Table S1.
bMean ± SD.
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also showed that KLK6 cleaved α-syn when the enzyme
was released from mitochondria under stress conditions.
KLK6 is also secreted in an active form extracellularly
and degrades extracellular α-syn [22]; this may be rele-
vant in preventing the transcellular spread of α-syn that is
thought to be important in the propagation of disease
[23,24]. Phosphorylated forms of α-syn which are more
abundant in Lewy body diseases, and mutant forms of
α-syn that accumulate in familial forms of PD, are resist-
ant to proteolytic cleavage by KLK6 [17]. A recent study
showed that elevating the level of KLK6 in vivo protected
against α-syn aggregation and toxicity in a rat model of
PD [25] and that KLK6 level was significantly lower in
mid-temporal cortex obtained post mortem from 8 pa-
tients with DLB than from 6 controls.
Calpains are calcium-dependant cysteine proteases in-
volved in multiple and diverse cellular processes. Calpain-1
(CAPN1, μ-calpain) and calpain-2 (CAPN2, m-calpain)
are regulated by micromolar and millimolar levels of
intracellular calcium, respectively, and unlike other mem-
bers of the calpain family are highly expressed within the
CNS. CAPN1 and CAPN2 are dysregulated in AD and
other tauopathies [26,27]. CAPN1 cleaves α-syn in vitro
[14,15]. It is neuronally expressed and likely to interact
with α-syn within the pre-synaptic terminal [28]. How-
ever, to our knowledge its activity in Lewy body diseases
has not been studied. CAPN1 cleaves monomeric α-syn
within the NAC region. This would be predicted to
prevent aggregation and neurotoxicity, and indeed the
addition of CAPN-1 cleavage fragments of monomeric
α-syn inhibited aggregation of the full-length monomers
[15]. However, cleavage of fibrillar rather than monomeric
α-syn by CAPN1 promoted the aggregation of full-length
α-syn [14,29] and might therefore be expected to acceler-
ate disease progression.
In this study, we investigated whether KLK6 level and
CAPN1 activity differed significantly between pure DLB,
AD and age-matched controls, in 4 grey matter regions
that vary in their predilection to Lewy body pathology:
parahippocampal, cingulate and frontal cortex, and pos-
terior thalamus. After establishing that KLK6 level and
CAPN1 activity were significantly reduced in cingulate
cortex in DLB, we showed that the reductions correlated
inversely with the levels of total α-syn and α-syn phosphor-
ylated at serine-129 (α-syn-P129). To assess the functional
relevance of down-regulation of KLK6 level and CAPN1,
we used SH-SY5Y neuroblastoma cells, within which there
was partial co-localisation of KLK6 and CAPN1 with
α-syn. Reduction of KLK6 and CAPN1 expression by
siRNA-mediated knock-down elevated endogenous α-syn
level within these cells. Together, our findings suggest that
reductions in KLK6 and CAPN1 contribute to the accu-
mulation of α-syn in sporadic DLB.Materials and methods
Study cohort
Brain tissue was obtained from the South West Dementia
Brain Bank, University of Bristol. The study had local
Research Ethics Committee approval. We examined DLB
(n = 12) and controls (n = 19) that were matched for age,
gender and post-mortem (PM) delay (Table 1, and the
MRC UK Brain Banks Network database identifiers are
listed in Additional file 1: Table S1). For further compari-
son, we also included an AD cohort (n = 20). The brains
had been separated midsagittally - the left half sliced and
frozen at −80°C and the right half fixed in formalin for
paraffin histology and detailed neuropathological exam-
ination. All disease cases were diagnosed using widely
accepted neuropathological criteria [30]. Pure DLB was di-
agnosed according to consensus neuropathological criteria
[31]. All DLB cases had Braak stage 5 or 6 Lewy body path-
ology [32]. Controls had no history of dementia and no
neuropathological abnormalities apart from mild neurofib-
rillary tangle pathology (Braak tangle stage III or less) [33]
and scattered diffuse Aβ plaques in some cases. No Lewy
body pathology was present in the substantia nigra or cere-
bral cortex in either the AD cases or the controls.
Immunohistochemical assessment of α-syn and α-syn-P129
Formalin-fixed paraffin-embedded sections of frontal,
cingulate, parahippocampal cortex and thalamus from
all DLB cases were immunolabeled for α-syn (80 μg/ml;
Vector Labs, Peterborough, UK) and α-syn-P129 (0.8 μg/ml;
Abcam) by means of a standard streptavidin-biotin-
HRP immunohistochemistry protocol [34]. The extent of
immunolabeling of each antigen was measured by field
fraction analysis with the help of Image Pro Plus™ software
(Media Cybernetics, Marlow, UK) driving a Leica DM
microscope with a motorized stage. The software made
an unbiased selection of twelve x20-objective fields and
the percentage area immunopositive for the relevant anti-
gen was determined for each section, as outlined previ-
ously [35,36].
Tissue preparation
Brain tissue was dissected from 4 cortical areas: parahip-
pocampal cortex (Brodmann area 36), cingulate cortex
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and posterior thalamus (pulvinar). Brain tissue (200 mg)
samples were sequentially extracted in 1% NP-40 buffer
(140 mM NaCl, 3 mM KCl, 25 mM Tris ph 7.4,
5 mM EDTA, 2 mM 1,10-phenanthroline, 0.1 M PMSF,
1.7 mg/ml aprotinin, NP-40 detergent, 100 ml dH2O)
(soluble extract) in a Precellys 24 homogeniser (Stretton
Scientific, Derbyshire, UK) with 2.3 mm ceramic beads
(Biospec, Glasgow, UK). The homogenates were spun at
13000 g for 15 min at 4°C and the supernatant was re-
moved and stored at −80°C. Insoluble material was solubi-
lized by vigorous agitation in 6 M GuHCl, re-homogenized
and left for 4 h at room temperature (RT) before storage
at −80°C.Total protein concentrations were determined
using the Total Protein Kit (Sigma Aldrich, Dorset, UK)
following the manufacturer’s guidelines.
CAPN1 fluorogenic activity assay
CAPN1 activity was measured in NP-40 soluble brain tis-
sue homogenates using an internally quenched fluorogenic
substrate for CAPN1 derived from the CAPN1-specific
cleavage site in α-spectrin (1 μM, H-K(FAM)-EYY ~
GMMK(DABCYL)-OH (Millipore)) in the presence of a
calpain-1 specific inhibitor (10 μM, Tocris, Bristol, UK).
Brain tissue homogenates (10 μl diluted in 40 μl assay buf-
fer) and purified human CAPN1 (Sigma Aldrich, Dorset,
UK) were diluted in assay buffer (50 mM Tris–HCl,
50 mM NaCl, 5 mM β-mercaptoethanol, 5 mM CaCl2,
1 mM EGTA, 1 mM EDTA) pre-warmed to 37°C as opti-
mised by Mittoo et al. [37]. Each sample and standard was
added to duplicate wells, with or without inhibitor and left
for 10 min at 37°C, prior to addition of the fluorogenic
substrate which was also diluted in assay buffer. The reac-
tion was left to proceed at 37°C for 3 h in the dark after
which fluorescence was read using a FLUOstar Optima
plate reader with excitation at 490 nm and emission at
518 nm. For each sample the fluorescent signal in the
inhibited wells was subtracted from that in the uninhibited
wells. Each sample was measured in duplicate and mea-
surements were repeated on two separate occasions.
Calpain-1 activity was interpolated from measurements on
serial dilutions of calpain-1 (20–1.25 μg/ml) that were in-
cluded in each plate.
KLK6 sandwich ELISA
KLK6 level was determined in NP-40 soluble brain tissue
homogenates using a sandwich ELISA that was devel-
oped in-house. Mouse monoclonal anti-KLK6 antibody
(Sigma Aldrich, Dorset, UK) diluted in PBS (1:200) left
overnight at room temperature (RT) in the wells of clear
Costar™ high-binding 96-well microplates (R&D systems,
Abingdon, UK). The plates were washed in PBS 0.01%
tween-20 and blocked for 3 h in 1%BSA/PBS at 26°C.
Tissue homogenates (6.5 μg total protein) and humanrecombinant standards (R&D systems, UK) diluted in
1% BSA/PBS were added overnight at 4°C. After another
5 washes, biotinylated goat polyclonal anti-KLK6 anti-
body (1 μg/ml) (R&D systems, Cambridge, UK) diluted
in 1% BSA/PBS, was added for 2 h at 26°C. After wash-
ing, streptavidin:HRP (1:200) (R&D systems, UK) diluted
in PBS/0.01% tween-20 was added for 1 h at 26°C, washed,
and chromogenic substrate (TMBS, R&D systems, UK)
was added for 20 min in the dark. The reaction was
stopped with 2 N sulphuric acid and absorbance read at
405 nM in a FLUOstar Optima plate reader. KLK6 level
was determined by interpolation against measurements
on serial dilutions of recombinant human KLK6 (720–
11.25 ng/ml). All sample measurements fell within the
calibration curve and measurements for each sample were
made in duplicate.
α-syn sandwich ELISA
α-syn level was determined in GuHCl solubilised brain
extracts by sandwich ELISA, as previously described
[38,39]. Mouse monoclonal anti-α-syn antibody (Syn-1,
raised against epitope corresponding to aa 91–99 [40])
(0.5 μg/ml) (BD Biosciences, Oxford, UK) was coated onto
a NUNC maxisorp 96-well plate overnight at RT. The
plate was washed in PBS/0.01% tween-20 and blocked for
1.5 h in 1% BSA/PBS. Tissue samples diluted in PBS were
added for 2 h at RT with constant shaking. Following a
further wash step, biotinylated goat polyclonal anti-α-syn
(raised against full-length recombinant human α-syn)
(1 μg/ml) (R&D systems, UK) was added for 2 h at RT.
After washing, streptavidin:HRP (1:200) (R&D systems)
was added for 20 min, the plates washed, and chromo-
genic substrate (TMBS, R&D system) was added for
20 min in the dark. The reaction was stopped with 2 N
sulphuric acid and absorbance at 405 nM read in a
FLUOstar Optima plate reader. Total α-syn level was de-
termined by interpolation against readings on serial dilu-
tions of recombinant human α-syn (62.5-0.97 ng/ml)
(rPeptide, Stratech, Suffolk, UK) on each plate. Measure-
ments for each sample were made in duplicate.
α-syn-P129 sandwich ELISA
α-syn-P129 level was determined in GuHCl solubilised
brain extracts by sandwich ELISA as previously de-
scribed [38,39]. Mouse monoclonal anti-α-syn antibody
(0.5 μg/ml) (BD Biosciences, Oxford, UK) was coated onto
a NUNC maxisorp 96-well plate overnight at RT. The
plate was washed in PBS/0.01% tween-20 and blocked for
1.5 h in 1% BSA/PBS. Tissue samples (1 μl plus 99 μl PBS)
were added for 5 h at RT with constant shaking. After
washing, biotinylated anti-α-syn-129 (0.8 μg/ml) (Abcam,
Cambridge, UK) was added at 4°C overnight. Following
washing, biotinylated horse anti-rabbit antibody (Vector
Labs, Burlingame, CA, USA) diluted 1:1000 in PBS with
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streptavidin:HRP (1:200) (R&D systems) was added for
20 min, the plates washed and chromogenic substrate
(TMBS, R&D system) was added for 20 min in the dark.
The reaction was stopped with 2 N sulphuric acid and
absorbance at 405 nM read in a FLUOstar Optima plate
reader. α-syn-P129 was determined by interpolation against
readings on serial dilutions (200–3.25 ng/ml) of recombin-
ant α-syn that had been phosphorylated at serine 129 by
incubation with casein kinase II (New England Biolabs,
Hitchin, UK) for 1 h at 30°C in the presence of ATP (New
England Biolabs).
The specificity of the α-syn-P129 detection antibody
used in the α-syn-P129 sandwich ELISA has previously
been confirmed by dot blot, as described in [39].
SH-SY5Y cell culture
SH-SY5Y neuroblastoma cells stably expressing human
full-length α-syn (SH-SY5Y-α-syn), were provided by Dr
Rohan de Silva, University College London (UCL), UK
and were generated by transfection with a pCDNA3.1
vector (Life Technologies, UK) containing wild-type hu-
man SNCA cDNA under the control of a CMV promoter,
as described [38]. Transfection was carried out with
TransFast (Promega) followed by selection of clones in
culture medium containing 0.3 mg/ml G418 (Geneticin,
Life Technologies). Stable clones were further maintained
in culture containing G418. SH-SY5Y-α-syn cells were
routinely maintained in 42% vol/vol Ham’s F12 nutrient
mixture (F12) (Sigma, UK), 42% vol/vol Eagle’s mini-
mum essential medium (MEM) (Sigma, UK), 15% vol/vol
foetal calf serum (FCS) (Sigma, UK), 2 mM l-glutamine
(Sigma, UK), 1% vol/vol non-essential amino acids (NEAA)
solution (Sigma, UK), 20 units/mL penicillin/20 mg/mL
streptomycin (Sigma, UK) and 250 ng/mL amphotericin B
(Life Technologies, UK) at 37°C in 5% CO2, 21% O2. SH-
SY5Y-α-syn cells were maintained under constant selec-
tion pressure by use of 0.3 mg/ml G418 (Geneticin, Life
Technologies).
siRNA knock-down of KLK6 and CAPN1
For siRNA-mediated transfection, SH-SY5Y-α-syn cells
were grown to 30-50% confluence. KLK6 and CAPN1
siRNA (10 nM) (Santa Cruz, Dallas, Texas, U.S.A) diluted
in Optimum™ (Invitrogen, Paisley, UK) was conjugated to
INTERFERin (Polyplus Transfection, Illkirch, France) ac-
cording to the manufacturer’s guidelines and added to the
cells. The culture medium was exchanged for fresh
complete medium after 4 h to minimise cellular toxicity.
After 4 d the cells were washed in PBS, detached in PBS
without magnesium and chloride (Sigma Aldrich, Dorset,
UK), pelleted and lysed in non-denaturing CellLyticTM
cell lysis buffer according to manufacturer’s guidelines
(Sigma Aldrich, Dorset, UK). The samples were centrifugedat 13,000 rpm for 15 min at 4°C and the supernatants ali-
quoted and stored at −80°C until used. Total protein level
was determined using Total Protein Kit (Sigma Aldrich,
Dorset, UK) and an equal amount of total protein from
each sample was added for measurement of KLK6 level,
CAPN1 activity and α-syn levels by sandwich ELISA or
activity assay, as described above.
Double immunofluorescent labeling of CAPN1/KLK6 and
α-syn
SH-SY5Y-α-syn cells were grown on poly-L-lysine coated
coverslips, washed in PBS x3, fixed in 4% paraformalde-
hyde for 10 min, further washed in PBS and blocked
for 30 min in PBS with 0.01% triton-X100 and 5%
horse serum (Millipore, Beeston, Nottingham, UK). Goat
polyclonal anti-KLK6 (2 μg/ml) (R&D systems, UK)
or rabbit polyclonal anti-CAPN1 (10 μg/ml) (BIOSS,
Woburn, Massachusetts, MA, USA) was added together
with mouse monoclonal α-syn (2.5 μg/ml) (BD, Oxford,
UK) for 1 h at RT. Alexa-fluor-488 and −555 (Invitrogen,
Life Technologies, Paisley, UK) were then added at 1:1000
for 1 h at RT in the dark. Images were acquired under a
x100 objective with a confocal scanning laser microscope.
Statistical analysis
Whenever possible, parametric statistical tests were used
for comparisons between groups (in some cases this re-
quired logarithmic transformation of the data to obtain a
normal distribution). ANOVA with Bonferroni post-hoc
test was used for multiple-group comparisons. For vari-
ables that were not normally distributed even after trans-
formation, Kruskall-Wallis test was used, with Dunn’s test
for pairwise intergroup comparisons. Pearson analysis was
used to assess the correlation between pairs of variables.
Statistical tests were performed using SPSS version 16.
P-values < 0.05 were considered statistically significant.
Results
CAPN1 activity is reduced in DLB and correlates inversely
with α-syn in regions affected by Lewy body pathology
We initially assessed α-syn and α-syn-P129 load within
the DLB cohort by standard immunoperoxidase labelling
(Figure 1a-b) and within brain extracts (extracted in
GuHCl) by sandwich ELISA in both control and DLB co-
horts (Figure 1c-d). Immunolabeling of α-syn (p = 0.004)
(Figure 1a) and α-syn-P129 (p = 0.0022) (Figure 1b) varied
significantly between regions and was highest in cingulate
cortex > parahippocampal cortex > frontal cortex > thalamus.
α-Syn level, measured by sandwich ELISA, did not vary sig-
nificantly between DLB and controls in any of the regions
(Figure 1c). However, α-syn-P129 was markedly elevated
in the cingulate cortex compared to other regions, and
α-syn-P129 level was higher in DLB than controls in all
regions, except for the frontal cortex (Figure 1d).
Figure 1 (See legend on next page.)
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Figure 1 Regional, disease-specific reduction in CAPN1 activity in DLB, and inverse correlation with α-syn load in human post-mortem
brain tissue. a α-syn and b α-syn-P129 immunopositive field fractions in DLB (there was no labelling in controls), and c α-syn and d α-syn-P129
levels in DLB and controls as measured by sandwich ELISA in brain tissue extracts, varied in a regional dependent-manner. The field fraction and
level of α-syn-P129 were highest in the cingulate cortex. The α-syn field fraction was also highest in the cingulate cortex (and lowest in the thalamus).
CAPN1 activity was significantly reduced in DLB in the e cingulate and f parahippocampal cortex but not in g frontal cortex or h thalamus. CAPN1 activity
was increased in the f parahippocampal gyrus in AD but not in other regions. In a combined cohort, CAPN1 activity tended to correlate inversely with the
levels of i-j α-syn, although this did not reach significance and significantly with k-l α-syn-P129 in the cingulate and parahippocampal cortex. In
the cingulate cortex, CAPN1 activity correlated inversely with m α-syn and n α-syn-P129 in the DLB group alone. In a-h the horizontal
bars indicate the mean value and SEM. In i-n the solid lines indicate best fit linear regression and the interrupted lines the 95% confidence
intervals. In all of the panels, each point represents a separate brain. *P < 0.05 ***P < 0.001.
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extracts for which we had measured α-syn and α-syn-
P129 in the DLB and control cohorts, in all four regions.
CAPN1 was significantly lower in pure DLB than age-
matched controls in the cingulate cortex (Figure 1e) and
parahippocampal cortex (Figure 1f ). CAPN1 activity was
not reduced in frontal cortex (Figure 1g) or thalamus
(Figure 1h). CAPN1 activity was significantly increased
in the parahippocampal cortex in AD (Figure 1f ). How-
ever, CAPN1 activity in AD brains was similar to that in
control brains in all other regions.
When the DLB and control cohorts were combined
for analysis a trend towards an inverse correlation was
observed between CAPN1 activity and α-syn in the cin-
gulate (Figure 1i) and parahippocampal cortex (Figure 1j)
but did not reach statistical significance. CAPN1 activity
was significantly correlated inversely with α-syn-P129 in
the cingulate (Figure 1k) and parahippocampus (Figure 1l).
In DLB cases alone, CAPN1 correlated inversely with α-
syn (Figure 1m) and α-syn-P129 (Figure 1n) in the cingu-
late cortex only. Correlations were not observed in the
frontal cortex or thalamus (data not shown).
KLK6 level is reduced in DLB and correlates inversely with
α-syn in the cingulate cortex
KLK6 level was significantly lower in pure DLB than in
age-matched controls in the cingulate cortex (Figure 2a)
and thalamus (Figure 2d). KLK6 was unaltered in the
frontal and parahippocampal cortex (Figure 2b-c). When
the DLB and control cohorts were combined for ana-
lysis, an inverse correlation was observed between KLK6
level and α-syn in the cingulate cortex that approached
significance (p = 0.06) (Figure 2e). A significant negative
correlation was observed between KLK6 level and α-syn-
P129 (Figure 2f ) in the cingulate cortex but not in any
other region.
CAPN1 and KLK6 co-localise with α-syn in vitro
To explore further the interaction between α-syn and the
two enzymes, CAPN1 and KLK6, we used human SH-SY5Y
cells transfected with full-length human SNCA. SH-SY5Y
cells overexpressing wild-type α-syn (SH-SY5Y-α-syn) had a
widespread, predominantly cytosolic distribution of α-syn(Figure 3a). KLK6 had a distinctive distribution pattern,
predominantly along the plasma membrane, and co-localised
with a minor fraction of endogenous α-syn (Figure 3a,
upper panels). CAPN1 had a more widespread punctate
cytosolic distribution and co-localised with α-syn within
the cytoplasm (Figure 3a, lower panels).
Reduction in CAPN1 or KLK6 causes an increase in
endogenous α-syn
To determine the functional significance of a potential
interaction between KLK6 or CAPN1 and α-syn, we ex-
amined the effect on α-syn level of siRNA mediated
knock-down of KLK6 or CAPN1 in SH-SY5Y-α-syn cells.
A small reduction in the expression of either enzyme
resulted in a significant increase in endogenous α-syn.
A 20% decrease in KLK6 level produced a ~25% in-
crease in α-syn (P < 0.01) (Figure 3b) and a 15% reduction
in CAPN1 activity resulted in a ~15% increase in α-syn
(P < 0.05) (Figure 3c).
Discussion
We have shown that (i) KLK6 and CAPN1 are reduced
in post-mortem brain tissue in DLB, in regions of cere-
bral cortex that show most marked accumulation of α-
syn, (ii) the amount of α-syn in these regions correlates
inversely with KLK6 and CAPN1 level and activity, (iii)
KLK6 and CAPN1 partially co-localised with α-syn in
SH-SY5Y cells overexpressing wild-type α-syn, and (iv)
the level of α-syn within these cells increases after
down-regulation of KLK6 and CAPN1 by siRNA knock-
down. The present findings suggest that impaired pro-
teolytic clearance by KLK6 and CAPN1 could contribute
to the accumulation of α-syn in DLB.
CAPN1 is expressed abundantly in neurons and is
enriched in pre-synaptic terminals where it may inter-
act physiologically with α-syn [28]. We have shown that
CAPN1 also co-localises with α-syn within the cytoplasm
of human SH-SY5Y cells, and have confirmed a previous
report [11] that siRNA-mediated reduction in CAPN1
results in a significant increase in endogenous wild-type
α-syn. In human cingulate and parahippocampal cortex,
regions with a predilection for α-syn pathology, we dem-
onstrated a ~50% reduction in CAPN1 activity in patients
Figure 2 Regional, disease-specific reduction in KLK6 level in DLB, and inverse correlation with α-syn load in human post-mortem
brain tissue. KLK6 level was reduced significantly in the a cingulate cortex and d thalamus in DLB but not in the b parahippocampal cortex or
c frontal cortex. In the cingulate cortex only, KLK6 correlated inversely with e total α-syn and f α-syn-P129 level. In a-d the horizontal bars indicate
the mean value and SEM. In e-f the solid lines indicate best fit linear regression and the interrupted lines the 95% confidence intervals. In all of
the panels, each point represents a separate brain. *P < 0.05.
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fully characterized [14,15,29] and the major cleavage site
located between amino acids 83–84 [14] is located within
the NAC region (aa 61–95) which is required for α-syn
aggregation [41,42]. Cleavage of α-syn by CAPN1 was
shown to inhibit aggregation of full-length α-syn [15].
Phosphorylation at serine-129 is the predominant modifi-
cation of α-syn in Lewy bodies and Lewy neurites [43,44]
and has been reported to mediate both the aggregation
and toxicity of α-syn [45-47]. A reduction in CAPN1
activity in cingulate and parahippocampal cortex would
therefore be expected to cause aggregation and accumula-
tion of α-syn and, indeed, we found that α-syn-P-129
levels correlated inversely with CAPN1 activity. The re-
duction in CAPN1 activity was regionally specific (it was
not observed in frontal cortex or thalamus) and was
also disease-specific in that a reduction was not ob-
served in AD.
Although these data may predict a role for reduced
CAPN1-mediated cleavage of α-syn in the pathogenesis
of Lewy body diseases, some questions remain. Firstly,
CAPN1 cleaves fibrillar, as well as monomeric α-syn,
to produce C-terminal fragments which promote theaggregation and neurotoxicity of full-length α-syn [14,15,29].
Thus CAPN1 may prevent the formation of Lewy bodies
from soluble monomeric α-syn but promote the aggrega-
tion and toxicity of aggregated species of α-syn. This may
explain why CAPN-specific inhibitors ameliorated neur-
onal and behavioural abnormalities in an experimental
mouse model of PD in which CAPN1 level was elevated
[48]. A recent study showed that overexpression of the en-
dogenous CAPN1 inhibitor, calpastatin, resulting in re-
duced calpain activity, reduced truncated and aggregated
α-syn and synaptic impairment in a mouse model of PD
[49]. Secondly, CAPN1 expression was also reportedly
elevated in post-mortem brain tissue in PD [48,50,51], in
contrast to our findings in DLB, although these studies re-
lied upon semi-quantitative immunohistochemical assess-
ment or measurement of spectrin rather than CAPN1
itself and did not measure enzyme activity. The regions
sampled might also account for these disease-specific dif-
ferences; for instance, the cortical regions we sampled in
DLB are mostly preserved compared to extensive neuro-
degeneration in subcortical areas in PD, such as the sub-
stantia nigra. Thirdly, we have not fully characterized the
levels of CAPN-1 specific cleavage fragments in our brain
Figure 3 KLK6 and CAPN1 are partially co-localised with α-syn and regulate its level in human SH-SY5Y neuroblastoma cells.
a Double-labelling immunofluorescence and confocal microscopy shows partial co-localisation of KLK6 and CAPN1 with α-syn. KLK6 (red)
has a distinctive distribution pattern, along the plasma membrane, where it co-localises with some of the α-syn (top merged image and
the magnified inset image). CAPN1 (green) has a widespread punctate cytosolic distribution and co-localises with α-syn within the cytoplasm (bottom
merged image and in the magnified inset image). b-c siRNA-mediated knock-down of KLK6 or CAPN1 in SH-SY5Y cells overexpressing α-syn
significantly increased endogenous α-syn level. The experiments were repeated in triplicate. The error bars represent the SEM. *P < 0.05 **P < 0.01.
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[14,15,29], or addressed whether CAPN1 specific substrates,
such as α-spectrin, vary in relation to CAPN1 activity.
Lastly, attempts should be made to address whether
reduction in CAPN1 activity in DLB in areas with sig-
nificant pathology represents a failed compensatory re-
sponse to increasing α-syn or occurs as a consequenceof disease. The former might explain why CAPN1 activities
are lowest in the thalamus, a region without significant
pathology. Alternatively, albeit less likely, it is possible that
individuals with lower CAPN1 activities are at greater risk
of developing DLB. In further studies of the possible role
of reduced CAPN1 activity in DLB it will be important to
consider the roles of CAPN1 in addition to its potential for
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intracellularly and has been implicated in the dysregulation
of autophagy [52-54] – implicated in both PD and DLB.
KLK6 is abundantly expressed within the brain, particu-
larly in neurons and oligodendrocytes [18-20]. It degrades
α-syn in vitro [16] and co-localises with Lewy bodies in
post-mortem brain tissue from people with PD [16,21].
Iwata A et al. [16] demonstrated an interaction between
KLK6 and α-syn in mouse brain by co-immunoprecipitation
and double-immunofluorescence. We have shown that
KLK6 is partly co-localised with α-syn in SH-SY5Y neuro-
blastoma cells, in a distinctive subplasmalemmal distribu-
tion, and confirmed that down-regulation of KLK6 results
in increased endogenous α-syn [16]. Like CAPN1, KLK6
cleaves monomeric α-syn within the NAC region, with a
major cleavage site between Lys80-Thr81 [17], and is
therefore predicted to protect against α-syn aggregation
and neurotoxicity by reducing monomeric α-syn level. Al-
though minor cleavage sites have been identified and are
predicted to produce C-terminal truncated α-syn frag-
ments [17], there is no evidence to date to suggest that
KLK6-mediated α-syn cleavage, unlike that mediated by
CAPN1 and other proteases such as cathepsin D [11] and
MMP [55], promotes α-syn aggregation. A recent study
demonstrated that elevating the level of KLK6 in vivo pro-
tected against α-syn aggregation and toxicity in a rat
model of PD [25] and that KLK6 level was reduced in hu-
man DLB post-mortem brain. KLK6 level is also reduced
in CSF in patients with synucleinopathy [56]. As is the
case for CAPN1, the phosphorylated and mutant forms of
α-syn that accumulate in sporadic and familial Lewy body
diseases are more resistant than wild-type unmodified
α-syn to cleavage by KLK6 [14,17]. Together, these data
provide a strong case for a regulatory role for KLK6 and
suggest that reduced KLK6-mediated cleavage of α-syn
and α-syn-P129 contribute to the pathogenesis of Lewy
body diseases.
As with CAPN1 several outstanding questions remain.
Firstly, it has been established that KLK6 is synthesised
as an inactive zymogen [20] and secreted extracellularly,
whereupon it is activated and degrades extracellular α-
syn [22]. This may be particularly important in prevent-
ing the transcellular spread of α-syn that is thought to
be important in the propagation of disease [23,24]. It is
unclear whether intracellular KLK6 is enzymatically ac-
tive; however, a previous study showed that under stress
conditions KLK6 is released from mitochondria into the
cytoplasm, where it can interact with and accelerate α-
syn degradation [16]. Our finding that KLK6 is partially
co-expressed with α-syn at the plasma membrane re-
quires confirmation but would be in keeping with a role
for KLK6 in the degradation of α-syn immediately after
endocytosis. Lastly, we have used a sandwich ELISA to
measure KLK6 protein level in brain tissue samples andhave used these measurements as a proxy measure for
KLK6 enzyme activity. This approach, however, requires
further validation as it is not always the case that protein
levels accurately reflect enzyme activity. Dysregulation of
KLK6 in DLB by mechanisms acting independently of α-
syn may also impact on disease progression. Recent find-
ings suggest that KLK6 indirectly mediates proteolysis of
α-syn by regulating the activation of an unidentified
metalloprotease [57].
Together, our findings support previous studies highlight-
ing a potential regulatory role of CAPN1 and KLK6 in the
metabolism of α-syn and suggest a role for reduced CAPN1
and KLK6 in the pathogenesis of DLB.
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